| B35 | Impact of baseline NNRTI pretreatment resistance mutations on risk of virologic failure of RPV-based dual therapies | E-poster | Regimen simplification and switch studies |
| B36 | Safety and pharmacokinetics of islatravir in study participants with severe renal insufficiency | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring |
| B37 | NNRTI MK-8507 does not alter the pharmacokinetics of the combined oral contraceptive levonorgestrel/ethinyl estradiol | E-poster | Drug interactions |
| B37 | Persistence of drug-drug interaction problems with contemporary antiretroviral therapy. The case of ergotism | E-poster | Drug interactions |
| B37 | No pharmacokinetic interaction between novel NNRTI MK-8507 and Islatravir | E-poster | Drug interactions |
| B38 | Long-term efficacy among participants switched to bictegravir/emtricitabinetTenofovir alafenamide (B/F/TAF) from dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) with preexisting resistance and viral blips | E-poster | Antiretroviral drug resistance |
| B38 | Kinetics of archived M184V mutation in HIV-DNA from highly experienced HIV-infected patients with sustained viral suppression | E-poster | Antiretroviral drug resistance |
| B38 | HIV-1 subtype influences the selection of resistance mutations and the resistance level to integrase inhibitors | E-poster | Antiretroviral drug resistance |
| B40 | Self-reported antiretroviral adherence: association with maternal viral load suppression in HIV-1-infected postpartum women in Promoting Maternal and Infant Survival Everywhere (PROMISE): randomized, open label trial in sub-Saharan Africa and India | E-poster | Adherence measurement |
| B40 | Estimating minimum adherence required for plasma HIV-1 RNA viral load suppression among people who use unregulated drugs in Vancouver, Canada | E-poster | Adherence measurement |